Download App

Log in to access Online Inquiry
Company Overview More
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
CEO: Galbraith C.A., Kenneth H.
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

ZYME Zymeworks
5.990+0.170+2.92%
Post Mkt Price
6.020+0.03+0.50%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
-26.96% 300.53M -40.75% 252.61M -40.75% 252.61M -34.78% 307.76M
-Cash and cash equivalents
-1.58% 275.52M -16.6% 201.87M -16.6% 201.87M 3.82% 253.44M
-Short-term investments
-80.98% 25.02M -72.47% 50.74M -72.47% 50.74M -76.15% 54.32M
Receivables
-7.6% 4.23M 2.1% 15.61M 2.1% 15.61M 33.45% 4.93M
-Accounts receivable
-7.6% 4.23M 2.1% 15.61M 2.1% 15.61M 33.45% 4.93M
Prepaid assets
15.21% 19.26M 48.92% 20M 48.92% 20M 104.57% 24.08M
Total current assets
-25.13% 324.02M -36.67% 288.22M -36.67% 288.22M -30.89% 336.76M
Non current assets
Net PPE
180.2% 49.7M 182.56% 49.77M 182.56% 49.77M 142.56% 43.13M
-Gross PPE
180.2% 49.7M 128.39% 63.83M 128.39% 63.83M 142.56% 43.13M
-Accumulated depreciation
-- -- -36.07% -14.06M -36.07% -14.06M -- --
Goodwill and other intangible assets
1.44% 34.35M -4.19% 33.48M -4.19% 33.48M -10.26% 32.34M
-Goodwill
0% 12.02M 0% 12.02M 0% 12.02M 0% 12.02M
-Other intangible assets
2.24% 22.33M -6.39% 21.47M -6.39% 21.47M -15.39% 20.33M
Investments and advances
0% 886K -96.58% 886K -96.58% 886K -96.57% 886K
Non current deferred assets
31.12% 3.49M 69.46% 4.28M 69.46% 4.28M 18.08% 2.95M
Non current prepaid assets
715.82% 17.53M 445.41% 12.49M 445.41% 12.49M 93.05% 4.28M
Total non current assets
84.94% 105.96M 21.14% 100.91M 21.14% 100.91M -0.95% 83.6M
Total assets
-12.26% 429.98M -27.72% 389.13M -27.72% 389.13M -26.47% 420.36M
Liabilities
Current liabilities
Payables
187.65% 14.03M -17.14% 5.17M -17.14% 5.17M 61.27% 5.05M
-accounts payable
187.65% 14.03M -17.14% 5.17M -17.14% 5.17M 61.27% 5.05M
Current accrued expenses
69.78% 56.44M 93.93% 54.25M 93.93% 54.25M -2.19% 40.7M
Current debt and capital lease obligation
-61.37% 1.15M -51.66% 1.31M -51.66% 1.31M -28.76% 1.35M
-Current capital lease obligation
-61.37% 1.15M -51.66% 1.31M -51.66% 1.31M -28.76% 1.35M
Other current liabilities
-89.47% 2.49M -80.21% 7.78M -80.21% 7.78M -58.75% 18.02M
Current liabilities
13.85% 79.97M -16.12% 71.85M -16.12% 71.85M -22.15% 75.43M
Non current liabilities
Long term debt and capital lease obligation
463.45% 30.69M 422.8% 31.02M 422.8% 31.02M 373.37% 28.85M
-Long term capital lease obligation
463.45% 30.69M 422.8% 31.02M 422.8% 31.02M 373.37% 28.85M
Non current deferred liabilities
0.05% 34.47M 1.16% 34.51M 1.16% 34.51M 2.38% 34.69M
Other non current liabilities
-13.3% 2.4M -3.18% 2.65M -3.18% 2.65M -1.2% 2.47M
Total non current liabilities
58.34% 67.56M 59.36% 68.19M 59.36% 68.19M 55.4% 66M
Total liabilities
30.66% 147.53M 9.02% 140.04M 9.02% 140.04M 1.48% 141.43M
Shareholders'equity
Share capital
13.37% 826.46M 2.34% 741.15M 2.34% 741.15M 3.39% 739.56M
-common stock
13.37% 826.46M 2.34% 741.15M 2.34% 741.15M 3.39% 739.56M
Retained earnings
-46.5% -755.73M -44.95% -683.1M -44.95% -683.1M -48.59% -643.95M
Paid-in capital
27.97% 218.37M 20.83% 197.71M 20.83% 197.71M 20.95% 189.98M
Gains losses not affecting retained earnings
0% -6.66M 0% -6.66M 0% -6.66M 0% -6.66M
Total stockholders'equity
-25.11% 282.44M -39.23% 249.09M -39.23% 249.09M -35.49% 278.93M
Total equity
-25.11% 282.44M -39.23% 249.09M -39.23% 249.09M -35.49% 278.93M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%